NYU Langone Medical Center and Lutheran Medical Center to create integrated healthcare network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NYU LANGONE Medical Center and Lutheran Medical Center will create a clinically integrated health care provider network for the New York metropolitan area.

This agreement creates a formal health system between the two organizations that extends NYU Langone’s presence in Brooklyn, while bolstering Lutheran’s access to NYU Langone’s vast offering of medical and surgical specialties. Regulatory approval for the combination and new health system entity are expected to be completed in 2015.

NYU Langone has multiple ambulatory sites throughout the region, in addition to its main Manhattan hospital campuses, and Lutheran, in collaboration with its affiliated health center, Lutheran Family Health Centers, operates an expansive network of ambulatory practices in four boroughs of New York.

“We have been working closely with Lutheran over the last several months to assess whether a partnership would benefit each of our institutions, the Brooklyn community and, most importantly, the patients and families who turn to us for help,” said Robert Grossman, dean and CEO of NYU Langone.

This affiliation agreement allows both institutions to respond to this changing landscape and stabilize health care delivery in Brooklyn. This will be accomplished by:

The affiliation will create a fully integrated delivery system in Brooklyn using Lutheran’s existing primary care network, develop a system-wide IT infrastructure, and will focus on key initiatives including maternal and child health, cancer services, cardiac and vascular services, and physician network development.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login